Published Date: 24 Apr 2023
Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.
Read Full News1.
Chemotherapy can be a challenging treatment?here's how to deal with some of the side-effects
2.
Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy
3.
Poor agreement between diagnostic tests for breast cancer-related lymphedema
4.
Targeted radiation offers promise in patients with metastasized small cell lung cancer to the brain
5.
EU Adds CAR-T Warning; New Blincyto Indication; Good News in Pancreatic Cancer
1.
Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection
2.
Liquid Biopsy: A Revolutionary Tool for Early Detection and Monitoring of Colorectal Cancer
3.
Unlocking the Potential of Onivyde: A New Hope for Cancer Treatment
4.
Cancer-Keeper Genes: Novel Therapeutic Targets for Disrupting Tumor Maintenance
5.
CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC - Part II
4.
From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL
5.
CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation